Cerenis Therapeutics:Â First Patient Enters Phase III TANGO Clinical Trial to Evaluate Efficacy to Regress Atherosclerosis and Safety of CER-001 in patients with Familial Primary HypoAlphalipoproteinemia (FPHA)